Compare Moderna, Inc. (MRNA) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Schwab US Large Cap Growth ETF — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while Schwab US Large Cap Growth ETF trades at $36.74 (market cap $65.01B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Moderna, Inc. is trading nearer its 52-week high, Schwab US Large Cap Growth ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and Schwab US Large Cap Growth ETF for 50 Days on average.
| MRNA | SCHG | |
|---|---|---|
Market Cap | $78.65B | $65.01B |
Volume | 37,373,437 | 8,554,399 |
Sector | Health | Sector/Thematic |
52-Week High | $203.46 | $36.93 |
52-Week Low | $22.36 | $28.10 |
Typical Hold Time | 59 Days | 50 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% on the day, with technical indicators showing a bullish trend and strong momentum. The stock has rallied over 500% in 2026, driven by positive clinical updates for its cancer vaccine pipeline and inclusion in the Nasdaq-100 index effective October 9, 2026. However, fundamentals remain challenging with revenue declining from $18.9B in 2022 to $1.9B in 2025 and negative net income margins exceeding 140%.
While technical momentum and pipeline optimism support near-term upside, valuation appears stretched with P/S of 35.08 and negative profitability metrics. Key risks include execution on non-COVID products, competitive pressure, and sustainability of recent gains. Analyst consensus is cautious with only 28% buy ratings and $115.70 price target suggesting significant downside from current levels.
SCHG (Schwab U.S. Large-Cap Growth ETF) trades at $36.42, down 1.22% with a bullish technical signal from moving averages. The ETF focuses on large-cap growth stocks with heavy concentration in top holdings like Apple. Recent news highlights SCHG's long-term growth potential and tax-efficient characteristics for retirement planning.
SCHG offers exposure to quality growth companies at a low 0.03% expense ratio, but faces concentration risk in top holdings. The ETF's performance depends heavily on megacap tech stocks, making it vulnerable to sector rotations. Long-term growth prospects remain strong based on historical performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
